<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabet Med</journal-id><journal-id journal-id-type="iso-abbrev">Diabet. Med</journal-id><journal-id journal-id-type="publisher-id">dme</journal-id><journal-title-group><journal-title>Diabetic Medicine</journal-title></journal-title-group><issn pub-type="ppub">0742-3071</issn><issn pub-type="epub">1464-5491</issn><publisher><publisher-name>BlackWell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25251842</article-id><article-id pub-id-type="pmc">4307641</article-id><article-id pub-id-type="doi">10.1111/dme.12593</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Articles</subject></subj-group></article-categories><title-group><article-title>The use of weighted health-related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Scanlon</surname><given-names>P H</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Loftus</surname><given-names>J</given-names></name><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Starita</surname><given-names>C</given-names></name><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Stratton</surname><given-names>I M</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><aff id="au1"><label>1</label><institution>Gloucestershire Diabetic Retinopathy Research Group, Gloucestershire Hospitals NHS Foundation Trust</institution><addr-line>Cheltenham, UK</addr-line></aff><aff id="au2"><label>2</label><institution>Pfizer Ltd</institution><addr-line>Walton Oaks, UK</addr-line></aff></contrib-group><author-notes><corresp id="cor1"><italic>Correspondence to:</italic> Peter H. Scanlon. E-mail: <email>peter.scanlon@glos.nhs.uk</email></corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>13</day><month>10</month><year>2014</year></pub-date><volume>32</volume><issue>1</issue><fpage>97</fpage><lpage>101</lpage><history><date date-type="accepted"><day>11</day><month>9</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2014 The Authors. Diabetic Medicine published by John Wiley &#x00026; Sons Ltd on behalf of Diabetes UK.</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><abstract><sec><title>Aims</title><p>To examine the relationship between visual acuity in each eye and Quality of Life (QoL) outcomes in people with diabetic macular oedema.</p></sec><sec><title>Methods</title><p>Cross sectional retrospective analysis of data collected at baseline in 289 people entered into a randomized clinical trial with diabetic macular oedema which investigated the safety and efficacy of a vascular endothelial growth factor inhibitor, pegaptanib sodium. At the baseline visit, visual acuity was measured through refraction and using retro-illuminated modified Early Treatment Diabetic Retinopathy Study Log MAR charts, and patient health-related QoL was determined using the European Quality of Life EQ&#x02013;5D&#x02013;3L and the Visual Functioning Questionnaire&#x02013;25 (NEI&#x02013;VFQ25). A regression analysis with QoL score from each vision-related domain as the dependent variable was fitted using linear and quadratic terms of the better and worse eye, age, gender, adjusted for number of concurrent conditions, ethnicity and level of diabetes control.</p></sec><sec><title>Results</title><p>For all vision-related QoL domains from NEI&#x02013;VFQ25 and EQ&#x02013;5D&#x02013;3L except ocular pain, both visual acuity in the better-seeing and the worse-seeing eye gave a significant increase in correlation coefficient over that obtained from clinical and demographic data. The NEI&#x02013;VFQ25 correlation was most closely associated with a weighted visual acuity measure of 0.75 in the better and 0.25 in the worse eye or 0.60 in the better and 0.40 in the worse eye.</p></sec><sec><title>Conclusions</title><p>We recommend that a weighted visual acuity measure from both eyes is considered in future diabetic macular oedema trials.</p></sec></abstract></article-meta></front><body><boxed-text position="float"><sec><title>What's new?</title><p><list list-type="bullet"><list-item><p>
This study is the first to highlight the importance of using both eyes in assessing Quality of Life in diabetic macular oedema using a weighting between the better- and worse-seeing eyes.
</p></list-item></list>
</p></sec></boxed-text><sec sec-type="intro"><title>Introduction</title><p>Diabetes is estimated to be increasing worldwide from 382&#x000a0;million in 2013 to 592&#x000a0;million in 2035 <xref rid="b1" ref-type="bibr">1</xref>, and is a major cause of morbidity worldwide <xref rid="b2" ref-type="bibr">2</xref>, with the incidence of diabetic retinopathy increasing in parallel. In people with diabetic retinopathy, the major cause of moderate vision loss is diabetic macular oedema, which can progress to cause increased visual impairment and eventual blindness, as defined by the World Health Authority definition of visual acuity (VA) &#x02264;&#x000a0;6/60 (log MAR &#x02265;&#x000a0;1.00) in the better-seeing eye <xref rid="b3" ref-type="bibr">3</xref>.</p><p>The health-related quality of life (HRQoL) of people with diabetic macular oedema is adversely affected at all stages of the disease <xref rid="b4" ref-type="bibr">4</xref>,<xref rid="b5" ref-type="bibr">5</xref>. Our current analysis was designed to use the baseline Quality of Life (QoL) EQ&#x02013;5D&#x02013;3L and NEI&#x02013;VFQ&#x000a0;25 data and the VA data from a recent clinical trial <xref rid="b6" ref-type="bibr">6</xref> to determine the impact of the level of vision in the better- and worse-seeing eye on QoL, as a relative weighting between the vision in the two eyes as had previously been suggested in people with macular degeneration by Pleil <italic>et&#x000a0;al</italic>. <xref rid="b7" ref-type="bibr">7</xref>.</p><p>The European Quality of Life (EuroQol) Group EQ&#x02013;5D&#x02013;3L <xref rid="b8" ref-type="bibr">8</xref> is a generic instrument for describing and valuing health. It consists of two parts, the first having five domains from which the responses are combined using an algorithm to provide a single index value using MVH weights <xref rid="b9" ref-type="bibr">9</xref>, for the health status of the individual; a score of 1 corresponds to perfect health, and a score of 0 corresponds to being dead. The second part of the tool is a visual analogue scale.</p><p>The second questionnaire was the National Eye Institute-Visual Functioning Questionnaire&#x000a0;25(NEI&#x02013;VFQ&#x000a0;25) <xref rid="b10" ref-type="bibr">10</xref>. It comprises 25 items to assess the difficulty of visual symptoms or day-to-day activities with 11 vision-related domains. All responses, apart from the general health question, are combined to provide a single composite score.</p></sec><sec sec-type="methods"><title>Methods</title><p>This retrospective analysis used baseline data from participants enrolled in the multicentre, Phase&#x000a0;2/3, randomized, sham-controlled, double-masked, 2-year, comparative trial (NCT&#x000a0;00605280) <xref rid="b11" ref-type="bibr">11</xref> in ophthalmology treatment centres in the USA, Canada, Australia, Europe, South America and India. Participants were &#x02265;&#x000a0;18&#x000a0;years of age with Type&#x000a0;1 or Type&#x000a0;2 diabetes and diabetic macular oedema involving the centre of the macula not associated with ischaemia. Participants were administered intravitreal injections of pegaptanib sodium 0.3&#x000a0;mg or sham injection every 6&#x000a0;weeks for up to 2&#x000a0;years. Details of inclusion and exclusion criteria, trial design and results can be obtained from the original publication of this trial <xref rid="b11" ref-type="bibr">11</xref>.</p><p>Patient HRQoL was determined using the two separate instruments, the EQ&#x02013;5D&#x02013;3L and the NEI&#x02013;VFQ&#x000a0;25 described above. Both instruments were administered to participants between the screening and baseline visit. In India, the two questionnaires were administered in the clinic by trained study personnel using paper-based versions which were faxed to the call centre for data entry onto the system. In all other centres, the questionnaires were administered in the participants&#x02019; local language by trained interviewers at a call centre and data were entered directly into a database.</p><p>In the trial, baseline VA was measured through refraction and using retro-illuminated modified Early Treatment Diabetic Retinopathy Study (ETDRS) Log MAR charts. Distance VA was expressed as an ETDRS score (number of letters correctly read) ranging from 0 to 94, where higher ETDRS scores represented better vision.</p><p>Linear regression models with QoL score from each vision-related domain and with the EQ&#x02013;5D index value as the dependent variables were fitted using linear and quadratic terms in the terms of the better and worse eye, age and gender, and were adjusted for number of concurrent conditions, ethnicity and level of diabetes control. Stepwise model selection procedures were used. All analyses were carried out using SAS v.&#x000a0;9.1.</p></sec><sec sec-type="results"><title>Results</title><p>The countries of origin of the 326 participants were: USA (50), Canada (7), Australia (5), South America (10), India (27) and Europe (188), including Austria (9), Czech Republic (69), Denmark (4), France (33), Germany (26), UK (7), Italy (25), the Netherlands (3), Portugal (10) and Switzerland (2).</p><p>Of the 326 participants, 37 did not have a composite VFQ result, i.e. they did not complete every section of the VFQ&#x000a0;25, and hence results are available for 289 participants in this trial with diabetic macular oedema, 55% were male and 82% were Caucasian (see Table<xref ref-type="table" rid="tbl1">1</xref>). The range of VA in the better-seeing eye was 35&#x02013;94 letters, median interquartile (IQR) range 69 (62&#x02013;77) letters. The range of VA in the worse-seeing eye was 0&#x02013;70, 56 (46&#x02013;63) letters. The correlation coefficient (<italic>r</italic><sup>2</sup>) between VA in the better and worse eyes was 0.57 (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001).</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p>Characteristics of the study population</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">
<italic>N</italic>
</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Gender</td><td align="left" rowspan="1" colspan="1">Men</td><td align="center" rowspan="1" colspan="1">160</td><td align="center" rowspan="1" colspan="1">55.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Women</td><td align="center" rowspan="1" colspan="1">129</td><td align="center" rowspan="1" colspan="1">44.6</td></tr><tr><td align="left" rowspan="5" colspan="1">Ethnicity</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="center" rowspan="1" colspan="1">237</td><td align="center" rowspan="1" colspan="1">82.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Asian</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">9.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Hispanic</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">4.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Black</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">2.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Other</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">1.4</td></tr><tr><td align="left" rowspan="2" colspan="1">Diabetes</td><td align="left" rowspan="1" colspan="1">Type 1</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">9.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Type 2</td><td align="center" rowspan="1" colspan="1">263</td><td align="center" rowspan="1" colspan="1">91.0</td></tr><tr><td align="left" rowspan="2" colspan="1">Smoker</td><td align="left" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">6.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">269</td><td align="center" rowspan="1" colspan="1">93.1</td></tr><tr><td align="left" rowspan="2" colspan="1">HbA1c</td><td align="left" rowspan="1" colspan="1">&#x0003c;&#x000a0;60&#x000a0;mmol/mol (&#x0003c;&#x000a0;7.6%)</td><td align="center" rowspan="1" colspan="1">135</td><td align="center" rowspan="1" colspan="1">46.7</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;&#x000a0;60&#x000a0;mmol/mol&#x02265;&#x000a0;7.6%)</td><td align="center" rowspan="1" colspan="1">154</td><td align="center" rowspan="1" colspan="1">53.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Body Mass Index (weight (kg)/(height (m)<sup>2</sup>)<xref ref-type="table-fn" rid="tf1-1">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">29.8 (5.5)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure (mmHg)<xref ref-type="table-fn" rid="tf1-1">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">138 (14)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)<xref ref-type="table-fn" rid="tf1-1">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">78 (9)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Visual acuity (ETDRS letters) in better eye<xref ref-type="table-fn" rid="tf1-1">*</xref></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">69 (61&#x02013;77)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Visual acuity (ETDRS letters) in better eye<xref ref-type="table-fn" rid="tf1-1">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">69.1 (11.7)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Visual acuity (ETDRS letters) in worse eye<xref ref-type="table-fn" rid="tf1-1">*</xref></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">56 (46&#x02013;63)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Visual acuity (ETDRS letters) in worse eye<xref ref-type="table-fn" rid="tf1-1">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">52.4 (13.4)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Number illnesses recorded<xref ref-type="table-fn" rid="tf1-1">*</xref></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">4 (2&#x02013;6)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="tf1-1"><label>*</label><p>Median (25th to 75th centiles); &#x02020;Mean (<sc>sd</sc>).</p></fn></table-wrap-foot></table-wrap><p>The results of the regression analyses (Table<xref ref-type="table" rid="tbl2">2</xref>) show that the proportion of variance in QoL scores explained by age group, gender, HbA<sub>1c</sub> group and ethnicity, although statistically significant, was not large (highest <italic>r</italic><sup>2</sup>&#x000a0;=&#x000a0;0.14 for driving).</p><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p>Regression analyses relating Quality of Life scores to vision</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="6" rowspan="1"/><th align="center" colspan="10" rowspan="1">Incremental <italic>r</italic><sup>2</sup> beyond age group, gender, HbA<sub>1c</sub> group, race</th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" rowspan="1" colspan="1">Mean score</th><th align="center" rowspan="1" colspan="1">
<sc>sd</sc>
</th><th align="center" rowspan="1" colspan="1"><italic>r</italic><sup>2</sup> for fitting age group, gender, HbA<sub>1c</sub> group, race</th><th align="center" rowspan="1" colspan="1">VA better eye</th><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">VA worse eye</th><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">0.75 VA better eye +0.25 VA worse eye</th><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">0.6 VA better eye +0.4 VA worse eye</th><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">0.5 VA better eye +0.5 VA worse eye</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" colspan="2" rowspan="1">General health</td><td align="left" rowspan="1" colspan="1">289</td><td align="left" rowspan="1" colspan="1">41.1</td><td align="left" rowspan="1" colspan="1">22.5</td><td align="left" rowspan="1" colspan="1">0.040</td><td align="left" rowspan="1" colspan="1">0.031</td><td align="center" rowspan="1" colspan="1">0.0027</td><td align="left" rowspan="1" colspan="1">0.019</td><td align="center" rowspan="1" colspan="1">0.0197</td><td align="left" rowspan="1" colspan="1">0.033</td><td align="center" rowspan="1" colspan="1">0.0018</td><td align="left" rowspan="1" colspan="1">0.032</td><td align="center" rowspan="1" colspan="1">0.0021</td><td align="left" rowspan="1" colspan="1">0.030</td><td align="center" rowspan="1" colspan="1">0.0027</td></tr><tr><td align="left" colspan="2" rowspan="1">General vision</td><td align="left" rowspan="1" colspan="1">289</td><td align="left" rowspan="1" colspan="1">54.3</td><td align="left" rowspan="1" colspan="1">17.8</td><td align="left" rowspan="1" colspan="1">0.017</td><td align="left" rowspan="1" colspan="1">0.137</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.098</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.152</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.152</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.148</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td></tr><tr><td align="left" colspan="2" rowspan="1">Ocular pain</td><td align="left" rowspan="1" colspan="1">289</td><td align="left" rowspan="1" colspan="1">78.8</td><td align="left" rowspan="1" colspan="1">22.9</td><td align="left" rowspan="1" colspan="1">0.061</td><td align="left" rowspan="1" colspan="1">0.002</td><td align="center" rowspan="1" colspan="1">0.4884</td><td align="left" rowspan="1" colspan="1">0.007</td><td align="center" rowspan="1" colspan="1">0.1469</td><td align="left" rowspan="1" colspan="1">0.003</td><td align="center" rowspan="1" colspan="1">0.3195</td><td align="left" rowspan="1" colspan="1">0.004</td><td align="center" rowspan="1" colspan="1">0.2479</td><td align="left" rowspan="1" colspan="1">0.005</td><td align="center" rowspan="1" colspan="1">0.2134</td></tr><tr><td align="left" colspan="2" rowspan="1">Near activities</td><td align="left" rowspan="1" colspan="1">289</td><td align="left" rowspan="1" colspan="1">57.9</td><td align="left" rowspan="1" colspan="1">23.7</td><td align="left" rowspan="1" colspan="1">0.029</td><td align="left" rowspan="1" colspan="1">0.158</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.094</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.169</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.164</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.157</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td></tr><tr><td align="left" colspan="2" rowspan="1">Distant activities</td><td align="left" rowspan="1" colspan="1">289</td><td align="left" rowspan="1" colspan="1">63.5</td><td align="left" rowspan="1" colspan="1">24.7</td><td align="left" rowspan="1" colspan="1">0.022</td><td align="left" rowspan="1" colspan="1">0.192</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.109</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.202</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.195</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.185</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td></tr><tr><td align="left" colspan="16" rowspan="1">Vision-specific</td></tr><tr><td align="left" colspan="2" rowspan="1">&#x02003;Social functioning</td><td align="left" rowspan="1" colspan="1">289</td><td align="left" rowspan="1" colspan="1">79.3</td><td align="left" rowspan="1" colspan="1">23.2</td><td align="left" rowspan="1" colspan="1">0.052</td><td align="left" rowspan="1" colspan="1">0.128</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.079</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.138</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.135</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.129</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td></tr><tr><td align="left" colspan="2" rowspan="1">&#x02003;Mental health</td><td align="left" rowspan="1" colspan="1">289</td><td align="left" rowspan="1" colspan="1">55.9</td><td align="left" rowspan="1" colspan="1">28.3</td><td align="left" rowspan="1" colspan="1">0.089</td><td align="left" rowspan="1" colspan="1">0.098</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.068</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.109</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.108</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.105</td><td align="left" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td></tr><tr><td align="left" colspan="2" rowspan="1">&#x02003;Role difficulties</td><td align="left" rowspan="1" colspan="1">289</td><td align="left" rowspan="1" colspan="1">54.4</td><td align="left" rowspan="1" colspan="1">28.3</td><td align="left" rowspan="1" colspan="1">0.059</td><td align="left" rowspan="1" colspan="1">0.080</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.080</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.097</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.102</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.102</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td></tr><tr><td align="left" colspan="2" rowspan="1">&#x02003;Dependency</td><td align="left" rowspan="1" colspan="1">289</td><td align="left" rowspan="1" colspan="1">68.4</td><td align="left" rowspan="1" colspan="1">31.3</td><td align="left" rowspan="1" colspan="1">0.109</td><td align="left" rowspan="1" colspan="1">0.094</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.088</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.113</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.117</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.117</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td></tr><tr><td align="left" colspan="2" rowspan="1">&#x02003;Driving</td><td align="left" rowspan="1" colspan="1">148</td><td align="left" rowspan="1" colspan="1">67.9</td><td align="left" rowspan="1" colspan="1">23.3</td><td align="left" rowspan="1" colspan="1">0.140</td><td align="left" rowspan="1" colspan="1">0.115</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.070</td><td align="center" rowspan="1" colspan="1">0.0006</td><td align="left" rowspan="1" colspan="1">0.127</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.127</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.123</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td></tr><tr><td align="left" colspan="2" rowspan="1">&#x02003;Colour vision</td><td align="left" rowspan="1" colspan="1">287</td><td align="left" rowspan="1" colspan="1">86.2</td><td align="left" rowspan="1" colspan="1">21.9</td><td align="left" rowspan="1" colspan="1">0.024</td><td align="left" rowspan="1" colspan="1">0.022</td><td align="center" rowspan="1" colspan="1">0.0112</td><td align="left" rowspan="1" colspan="1">0.030</td><td align="center" rowspan="1" colspan="1">0.0032</td><td align="left" rowspan="1" colspan="1">0.030</td><td align="center" rowspan="1" colspan="1">0.0034</td><td align="left" rowspan="1" colspan="1">0.033</td><td align="center" rowspan="1" colspan="1">0.0021</td><td align="left" rowspan="1" colspan="1">0.034</td><td align="center" rowspan="1" colspan="1">0.0017</td></tr><tr><td align="left" colspan="2" rowspan="1">&#x02003;Peripheral vision</td><td align="left" rowspan="1" colspan="1">288</td><td align="left" rowspan="1" colspan="1">71.4</td><td align="left" rowspan="1" colspan="1">25.9</td><td align="left" rowspan="1" colspan="1">0.023</td><td align="left" rowspan="1" colspan="1">0.084</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.095</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.106</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.114</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.116</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td></tr><tr><td align="left" colspan="2" rowspan="1">&#x02003;Composite</td><td align="left" rowspan="1" colspan="1">289</td><td align="left" rowspan="1" colspan="1">66.2</td><td align="left" rowspan="1" colspan="1">19.2</td><td align="left" rowspan="1" colspan="1">0.060</td><td align="left" rowspan="1" colspan="1">0.160</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.135</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.186</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.190</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td><td align="left" rowspan="1" colspan="1">0.188</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.0001</td></tr><tr><td align="left" colspan="2" rowspan="1">&#x02003;EQ5D</td><td align="left" rowspan="1" colspan="1">289</td><td align="left" rowspan="1" colspan="1">0.738</td><td align="left" rowspan="1" colspan="1">0.2</td><td align="left" rowspan="1" colspan="1">0.071</td><td align="left" rowspan="1" colspan="1">0.019</td><td align="center" rowspan="1" colspan="1">0.0160</td><td align="left" rowspan="1" colspan="1">0.033</td><td align="center" rowspan="1" colspan="1">0.0015</td><td align="left" rowspan="1" colspan="1">0.027</td><td align="center" rowspan="1" colspan="1">0.0038</td><td align="left" rowspan="1" colspan="1">0.032</td><td align="center" rowspan="1" colspan="1">0.0019</td><td align="left" rowspan="1" colspan="1">0.033</td><td align="center" rowspan="1" colspan="1">0.0014</td></tr></tbody></table><table-wrap-foot><fn><p>Some items, e.g. driving have a response choice that indicates that the respondent does not perform the activity for reasons unrelated to vision. If a respondent selects this choice, the answer is treated as missing and an average of the remaining items is calculated. This is the reason for the reduced number in some domains.</p></fn></table-wrap-foot></table-wrap><p>Table<xref ref-type="table" rid="tbl2">2</xref> shows the relative contributions of the better- and worse-seeing eyes to the QoL scores, alone and in combination of better seeing/worse seeing 0.75/0.25, then 0.60/0.40 and the last being 0.50/0.50. These combinations were chosen with higher contributions in the better-seeing eye because <italic>r</italic><sup>2</sup> values for the NEI&#x02013;VFQ&#x000a0;25 in Table<xref ref-type="table" rid="tbl2">2</xref> show that the contribution of the worse eye is less than that of the better-seeing eye.</p><p>There was a relationship (<italic>P</italic>&#x000a0;=&#x000a0;0.016) between EQ&#x02013;5D&#x02013;3L scores and VA in the better-seeing eye, for those with a VA in the better eye of &#x0003c;&#x000a0;60 letters, the median EQ&#x02013;5D&#x02013;3L score was 0.73 (0.59&#x02013;0.81), and for those with a VA of &#x02265;&#x000a0;80 in the better-seeing eye, the median EQ&#x02013;5D&#x02013;3L score was 0.80 (0.69&#x02013;0.94).</p><p>By using the QoL data, the current analysis did not show a strong correlation (levels of 0.027&#x02013;0.033) with the EQ&#x02013;5D&#x02013;3L.</p><p>For the NEI&#x02013;VFQ&#x000a0;25, there was no relationship between VA in either eye and ocular pain. There was a stronger correlation between visual loss and other QoL domains (e.g. distance 0.185&#x02013;0.202 and near 0.157&#x02013;0.169) and composite scores (0.186&#x02013;0.19) using the NEI&#x02013;VFQ&#x000a0;25. This links most closely to the visual loss in the better-seeing eye, but there is also a correlation with the worse-seeing eye. For all other vision-related QoL domains the VA in both the better and the worse eye gave a significant increase in <italic>r</italic><sup>2</sup>. Different combinations of VA in the better- and worse-seeing eyes show different effects on the QoL scores. For all but colour and peripheral vision, the increase was significantly larger for VA in the better than the worse-seeing eye.</p><p>For the three combinations of VA in the better- and worse-seeing eyes presented in Table<xref ref-type="table" rid="tbl2">2</xref>, the incremental increase in <italic>r</italic><sup>2</sup> was larger for combinations of VA in the better- and worse-seeing eyes than for either eye alone. The domains for which this was greatest were for the composite scores of peripheral vision, role difficulties and dependency.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>In 2002, Brown <italic>et&#x000a0;al</italic>. <xref rid="b12" ref-type="bibr">12</xref> reported that visual loss caused a diminution in self-assessed quality of life but did not appear to be affected by the presence of co-morbidities. However, Davidov <italic>et&#x000a0;al</italic>. <xref rid="b4" ref-type="bibr">4</xref> found that, as well as ocular disease levels of diabetic retinopathy, patient co-morbidities lead to significant impairment of both the physical and mental components of the HRQoL. A study of the impact of laser treatment <xref rid="b13" ref-type="bibr">13</xref> concluded that, after a pronounced reduction of quality-of-life impacts following the first laser treatment, there was an increasing negative impact as people move from first treatment to multiple treatments.</p><p>Previous studies <xref rid="b5" ref-type="bibr">5</xref>,<xref rid="b14" ref-type="bibr">14</xref> have demonstrated a correlation between lower QoL scores using the NEI&#x02013;VFQ&#x000a0;25 and loss of vision in diabetic macular oedema and proliferative diabetic retinopathy.</p><p>This study does have some limitations:</p><p><list list-type="order"><list-item><p>
The insensitivity of the EQ&#x02013;5D for visual disorders is well established <xref rid="b15" ref-type="bibr">15</xref>,<xref rid="b16" ref-type="bibr">16</xref>.
</p></list-item><list-item><p>
Furthermore, mapping NEI&#x02013;VFQ&#x000a0;25 scores to EQ&#x02013;5D utilities has been shown to provide low predictive power, suggesting an inability of the EQ&#x02013;5D to discriminate vision-related activities <xref rid="b17" ref-type="bibr">17</xref>.
</p></list-item></list></p><p>However, the EQ&#x02013;5D is an important tool that is used to determine cost-effectiveness for appraisals of new pathways and treatments by the National Institute for Health and Clinical Excellence (NICE) in England. We believe that, in such appraisals, data from both eyes should be used.</p><p>A recent review <xref rid="b18" ref-type="bibr">18</xref> found a stronger correlation between health state utility values (HSUVs) and better-seeing eye VA compared with worse-seeing eye VA. Our study has demonstrated that the VA in both eyes needs to be considered and is the first study to report a correlation between VA in the better- and worse-seeing eyes in diabetic macular oedema.</p><p>We would recommend that a weighted VA measure of 0.75 in the better and 0.25 in the worse eye, or 0.60 in the better and 0.40 in the worse eye is used in future diabetic macular oedema trials because this study has demonstrated that the most information can be provided by taking into account vision in both eyes when determining the effect on quality of life.</p></sec><sec><title>Funding sources</title><p>This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.</p></sec><sec><title>Competing interests</title><p>JL and CS are employees of Pfizer. PS sat on the European Advisory Board for Pfizer in 2010&#x02013;11 advising on Quality of Life studies. IS has no competing interests.</p></sec></body><back><ack><p>We are very grateful to all the participants and investigators and the study team who were involved in the study and provided data for the analysis. We would also like to acknowledge Dr A Pleil for his useful comments about the first draft of this manuscript.</p></ack><ref-list><title>References</title><ref id="b1"><element-citation publication-type="other"><collab>International Diabetes Federation</collab><year>2013</year><comment>IDF Diabetes Atlas. Available at <ext-link ext-link-type="uri" xlink:href="http://www.idf.org/diabetesatlas">http://www.idf.org/diabetesatlas</ext-link> Last accessed 16 April 2014</comment></element-citation></ref><ref id="b2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Resnikoff</surname><given-names>S</given-names></name><name><surname>Pascolini</surname><given-names>D</given-names></name><name><surname>Etya'ale</surname><given-names>D</given-names></name><name><surname>Kocur</surname><given-names>I</given-names></name><name><surname>Pararajasegaram</surname><given-names>R</given-names></name><name><surname>Pokharel</surname><given-names>GP</given-names></name><etal/></person-group><article-title>Global data on visual impairment in the year 2002</article-title><source>Bull World Health Org</source><year>2004</year><volume>82</volume><fpage>844</fpage><lpage>851</lpage><pub-id pub-id-type="pmid">15640920</pub-id></element-citation></ref><ref id="b3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keenan</surname><given-names>TD</given-names></name><name><surname>Johnston</surname><given-names>RL</given-names></name><name><surname>Donachie</surname><given-names>PHJ</given-names></name><name><surname>Sparrow</surname><given-names>JM</given-names></name><name><surname>Stratton</surname><given-names>IM</given-names></name><name><surname>Scanlon</surname><given-names>PH</given-names></name></person-group><article-title>United Kingdom National Ophthalmology Database Study: Diabetic Retinopathy; Report 1: prevalence of centre-involving diabetic macular oedema and other grades of maculopathy and retinopathy in hospital eye services</article-title><source>Eye (Lond)</source><year>2013</year><volume>27</volume><fpage>1397</fpage><lpage>1404</lpage><pub-id pub-id-type="pmid">24051410</pub-id></element-citation></ref><ref id="b4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidov</surname><given-names>E</given-names></name><name><surname>Breitscheidel</surname><given-names>L</given-names></name><name><surname>Clouth</surname><given-names>J</given-names></name><name><surname>Reips</surname><given-names>M</given-names></name><name><surname>Happich</surname><given-names>M</given-names></name></person-group><article-title>Diabetic retinopathy and health-related quality of life</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2009</year><volume>247</volume><fpage>267</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">18925408</pub-id></element-citation></ref><ref id="b5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hariprasad</surname><given-names>SM</given-names></name><name><surname>Mieler</surname><given-names>WF</given-names></name><name><surname>Grassi</surname><given-names>M</given-names></name><name><surname>Green</surname><given-names>JL</given-names></name><name><surname>Jager</surname><given-names>RD</given-names></name><name><surname>Miller</surname><given-names>L</given-names></name></person-group><article-title>Vision-related quality of life in patients with diabetic macular oedema</article-title><source>Br J Ophthalmol</source><year>2008</year><volume>92</volume><fpage>89</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">17584999</pub-id></element-citation></ref><ref id="b6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sultan</surname><given-names>MB</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Loftus</surname><given-names>J</given-names></name><name><surname>Dombi</surname><given-names>T</given-names></name><name><surname>Ice</surname><given-names>KS</given-names></name></person-group><article-title>A phase 2/3, multicenter, randomized, double-masked, 2&#x02013;year trial of pegaptanib sodium for the treatment of diabetic macular edema</article-title><source>Ophthalmology</source><year>2011</year><volume>118</volume><fpage>1107</fpage><lpage>1118</lpage><pub-id pub-id-type="pmid">21529957</pub-id></element-citation></ref><ref id="b7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pleil</surname><given-names>AM</given-names></name><name><surname>Cappelleri</surname><given-names>JC</given-names></name><name><surname>Chisholm</surname><given-names>JA</given-names></name><name><surname>Getter</surname><given-names>CA</given-names></name><name><surname>Lustig</surname><given-names>S</given-names></name><name><surname>Reichel</surname><given-names>MB</given-names></name></person-group><article-title>An interpretation of quality of life based on binocular visual acuity in German patients with age-related macular degeneration</article-title><source>Invest Ophthalmol Vis Sci</source><year>2004</year><fpage>45</fpage><comment>. Available at <ext-link ext-link-type="uri" xlink:href="http://abstracts.iovs.org/cgi/content/abstract/45/5/1369">http://abstracts.iovs.org/cgi/content/abstract/45/5/1369</ext-link> Last accessed 16 April 2014</comment></element-citation></ref><ref id="b8"><element-citation publication-type="other"><collab>EuroQol Group</collab><year>2013</year><comment>EQ-5D User Guide. Available at <ext-link ext-link-type="uri" xlink:href="http://www.euroqol.org/about-eq-5d/publications/user-guide.html">http://www.euroqol.org/about-eq-5d/publications/user-guide.html</ext-link> Last accessed 16 April 2014</comment></element-citation></ref><ref id="b9"><element-citation publication-type="book"><collab>MVH_Group</collab><source>The Measurement and Valuation of Health: Final Report on the Modelling of Valuation Tariffs</source><year>1995</year><publisher-name>Centre for Health Economics, University of York</publisher-name></element-citation></ref><ref id="b10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangione</surname><given-names>CM</given-names></name><name><surname>Lee</surname><given-names>PP</given-names></name><name><surname>Gutierrez</surname><given-names>PR</given-names></name><name><surname>Spritzer</surname><given-names>K</given-names></name><name><surname>Berry</surname><given-names>S</given-names></name><name><surname>Hays</surname><given-names>RD</given-names></name></person-group><article-title>Development of the 25-item National Eye Institute Visual Function Questionnaire</article-title><source>Arch Ophthalmol</source><year>2001</year><volume>119</volume><fpage>1050</fpage><lpage>1058</lpage><pub-id pub-id-type="pmid">11448327</pub-id></element-citation></ref><ref id="b11"><element-citation publication-type="other"><collab>Clinical Trials.gov</collab><comment>A Multi-Center Trial to Evaluate the Safety and Efficacy of Pegaptanib Sodium (Macugen) Injected into the Eye Every 6 Weeks for up to 2&#x000a0;Years for Macular Swelling Associated with Diabetes, with an Open-Label Macugen Year Extension. Available at <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/results/NCT00605280">clinicaltrials.gov/ct2/show/results/NCT00605280</ext-link> Last accessed 16 April 2014</comment></element-citation></ref><ref id="b12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>MM</given-names></name><name><surname>Brown</surname><given-names>GC</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Hollands</surname><given-names>H</given-names></name><name><surname>Landy</surname><given-names>J</given-names></name></person-group><article-title>Quality of life and systemic comorbidities in patients with ophthalmic disease</article-title><source>Br J Ophthalmol</source><year>2002</year><volume>86</volume><fpage>8</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">11801494</pub-id></element-citation></ref><ref id="b13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scanlon</surname><given-names>PH</given-names></name><name><surname>Martin</surname><given-names>ML</given-names></name><name><surname>Bailey</surname><given-names>C</given-names></name><name><surname>Johnson</surname><given-names>E</given-names></name><name><surname>Hykin</surname><given-names>P</given-names></name><name><surname>Keightley</surname><given-names>S</given-names></name></person-group><article-title>Reported symptoms and quality-of-life impacts in patients having laser treatment for sight-threatening diabetic retinopathy</article-title><source>Diabetes Med</source><year>2006</year><volume>23</volume><fpage>60</fpage><lpage>66</lpage></element-citation></ref><ref id="b14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Nemesure</surname><given-names>B</given-names></name><name><surname>Hennis</surname><given-names>A</given-names></name><name><surname>Leske</surname><given-names>M</given-names></name></person-group><article-title>Visual acuity impairment and vision-related quality of life: the Barbados Eye Studies</article-title><source>Br J Visual Impairment</source><year>2009</year><volume>27</volume><fpage>9</fpage><lpage>24</lpage></element-citation></ref><ref id="b15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenwick</surname><given-names>EK</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Ratcliffe</surname><given-names>J</given-names></name><name><surname>Pesudovs</surname><given-names>K</given-names></name><name><surname>Finger</surname><given-names>RP</given-names></name><name><surname>Wong</surname><given-names>TY</given-names></name><etal/></person-group><article-title>The impact of diabetic retinopathy and diabetic macular edema on health-related quality of life in type 1 and type 2 diabetes</article-title><source>Invest Ophthalmol Vis Sci</source><year>2012</year><volume>53</volume><fpage>677</fpage><lpage>684</lpage><pub-id pub-id-type="pmid">22205611</pub-id></element-citation></ref><ref id="b16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tosh</surname><given-names>J</given-names></name><name><surname>Brazier</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>P</given-names></name><name><surname>Longworth</surname><given-names>L</given-names></name></person-group><article-title>A review of generic preference-based measures of health-related quality of life in visual disorders</article-title><source>Value Health</source><year>2012</year><volume>15</volume><fpage>118</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">22264979</pub-id></element-citation></ref><ref id="b17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kay</surname><given-names>S</given-names></name><name><surname>Ferreira</surname><given-names>A</given-names></name></person-group><article-title>Mapping the 25-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) to EQ-5D utility scores</article-title><source>Ophthalmic Epidemiol</source><year>2014</year><volume>21</volume><fpage>66</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">24568628</pub-id></element-citation></ref><ref id="b18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poku</surname><given-names>E</given-names></name><name><surname>Brazier</surname><given-names>J</given-names></name><name><surname>Carlton</surname><given-names>J</given-names></name><name><surname>Ferreira</surname><given-names>A</given-names></name></person-group><article-title>Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: a systematic review</article-title><source>BMC Ophthalmol</source><year>2013</year><volume>13</volume><fpage>74</fpage><pub-id pub-id-type="pmid">24304921</pub-id></element-citation></ref></ref-list></back></article>